A Phase 3 interventional study of Placebo and Gevokizumab in Behcet's Disease Uveitis, sponsored by XOMA (US) LLC. Terminated at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-29.
Sponsored by XOMA (US) LLC · Phase 3, Interventional, and Treatment
The objective of this study is to assess the efficacy and safety of gevokizumab in treating Behcet's disease uveitis (BDU).
136 studies on the registry are indexed under Behcet Syndrome; 43 are open to participants now.
This study's enrollment of 4 is below the median of 50 across 70 interventional studies indexed under Behcet Syndrome.
Browse Behcet Syndrome studies →XOMA (US) LLC is the lead sponsor of 25 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Drug: Placebo
Drug: Gevokizumab
Solution for subcutaneous injection
Solution for subcutaneous injection
Time to first ocular exacerbation
Time to first ocular exacerbation is defined as the number of days from randomization to the first ocular exacerbation.
Time frame: Randomization through Day 280
This study is terminated, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
XOMA (US) LLC